Scholarly record
APPLICATION OF MESOPOROUS SILICA IN HOSTING AND CONTROLLED RELEASE OF SODIUM ALENDRONATE
Publication Impact Profile
- Captures
- Mendeley - Readers: 2
Publication details
References28
Whitaker M., Guo J., Kihoe T., Benson G. Bisphosphonates for osteoporosis e where do we go from here N Engl J Med 2012; 366(22):2048-51.
Black D.M., Bauer D.C., Schwartz A.V., et al. Continuing bisphosphonate treatment for osteoporosis for whom and for how long N Engl J Med 2012; 366(22):2051-3.
Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25:976-82.
Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years’ experience w ith alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-99.
***Medication Guide Fosama Plus ® Reference ID: 3403221 accessed via the internet at: http://www.fda.gov/downloads/Drugs/DrugSafety.
Bonnick S., Saag K., Kiel D. et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab, 2006; 91: 2631-2637.
***Doc. Ref.: EMEA/360723/2009, accessed via the internet at http://www.emea. europa.eu/humandocs/PDFs/EPAR/Fosavance/23778305en.
Zarowitz B.J. Bisphosphonate Duration of Therapy for Management of Osteoporosis. J Geri Nurse 2012; 33(6): 479-481.
Whitaker M., Guo J., Kehoe T. et al . Bisphosphonate agents for osteoporosis- where do we go from here N Eng l J Med. 2012; 366: 2051–2053.
***United States Pharmacopeia 32, National Formulary 27, New York, 2009:1013.
Rouquerol F., Rouquerol J., Sing K., Adsorption by powders and porous solids, Methodology and applications, Academic Press, London, 1999.
Dolatabadi J.E.N., Hamishehkar H., Eskandani M., Valizadeh H., Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles, Coll. Surf. B: Biointerf. 2014; 117: 21 – 28.
J.P. Blitz, R.S. Murthy and D.E. Leyden, J. Coll. Interf. Sci., 1998; 126: 387.
Baltes M., Cassiers K., et al., MCM-48 -Supported Vanadium Oxide Catalysts, Prepared by the molecular designed dispersion of VO(acac) 2: a detailed study of the highly reactive MCM-48 surface and the structure and activity of the deposited VOx, J. Catal., 2001; 197: 160 – 171. International Multidisciplinary Scientific GeoConfenferences SGEM 2015 www.sgem.org
Whitaker M., Guo J., Kihoe T., Benson G. Bisphosphonates for osteoporosis e where do we go from here N Engl J Med 2012; 366(22):2048-51.
Black D.M., Bauer D.C., Schwartz A.V., et al. Continuing bisphosphonate treatment for osteoporosis for whom and for how long N Engl J Med 2012; 366(22):2051-3.
Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25:976-82.
Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years’ experience w ith alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-99.
***Medication Guide Fosama Plus ® Reference ID: 3403221 accessed via the internet at: http://www.fda.gov/downloads/Drugs/DrugSafety.
Bonnick S., Saag K., Kiel D. et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab, 2006; 91: 2631-2637.
***Doc. Ref.: EMEA/360723/2009, accessed via the internet at http://www.emea. europa.eu/humandocs/PDFs/EPAR/Fosavance/23778305en.
Zarowitz B.J. Bisphosphonate Duration of Therapy for Management of Osteoporosis. J Geri Nurse 2012; 33(6): 479-481.
Whitaker M., Guo J., Kehoe T. et al . Bisphosphonate agents for osteoporosis- where do we go from here N Eng l J Med. 2012; 366: 2051–2053.
***United States Pharmacopeia 32, National Formulary 27, New York, 2009:1013.
Rouquerol F., Rouquerol J., Sing K., Adsorption by powders and porous solids, Methodology and applications, Academic Press, London, 1999.
Dolatabadi J.E.N., Hamishehkar H., Eskandani M., Valizadeh H., Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles, Coll. Surf. B: Biointerf. 2014; 117: 21 – 28.
J.P. Blitz, R.S. Murthy and D.E. Leyden, J. Coll. Interf. Sci., 1998; 126: 387.
Baltes M., Cassiers K., et al., MCM-48 -Supported Vanadium Oxide Catalysts, Prepared by the molecular designed dispersion of VO(acac) 2: a detailed study of the highly reactive MCM-48 surface and the structure and activity of the deposited VOx, J. Catal., 2001; 197: 160 – 171. International Multidisciplinary Scientific GeoConfenferences SGEM 2015 www.sgem.org
View or Download full articleAccess options
SWS access login
Login as SWS Scientific CommitteeLogin as SWS Scientific PartnerLogin as SWS AuthorAuthors and approved SWS contributors will read and export their own linked papers after identity matching by SWS profile, email and SGEM GlobalID.
For librarian assistance: [email protected]
Purchase Instant Access
- Article can be downloaded after successful payment.
- Article may be used according to SWS library access terms.
- Article cannot be redistributed.